Serious doubts on safety and efficacy of CCR5 antagonists : CCR5 antagonists teeter on a knife-edge.
Horster
S
S
Department of Infectious Diseases, Medical Policlinic, Ludwig Maximilian University Munich, Pettenkoferstr. 8a, 80336 Munich, Germany.
Goebel
F D
FD
D001565:Benzoates / Q000009:adverse effects / Q000627:therapeutic use; D065100:CCR5 Receptor Antagonists; D002986:Clinical Trials as Topic; D017322:Clinical Trials, Phase II as Topic; D003510:Cyclohexanes / Q000009:adverse effects / Q000627:therapeutic use; D054659:Diketopiperazines; D023581:HIV Fusion Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D000077592:Maraviroc; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use; D013141:Spiro Compounds / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use
D001565:Benzoates; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D054659:Diketopiperazines; D023581:HIV Fusion Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D013141:Spiro Compounds; D014230:Triazoles; C499671:aplaviroc; D000077592:Maraviroc; C486781:vicriviroc